Putnam Investments LLC Nektar Therapeutics Transaction History

Putnam Investments LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $6.3 Million - $7.78 Million	-381,600 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $6.32 Million - $9.72 Million	381,600 New	381,600 $7.63 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $165,600 - $308,289	-5,442 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $322,850 - $475,937	-6,949 Reduced 56.08%	5,442 $332,000
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $2.02 Million - $4.57 Million	-43,731 Reduced 77.92%	12,391 $605,000

Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $1.67 Million - $3.16 Million	-29,143 Reduced 34.18%	56,122 $5.96 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $402,481 - $1.06 Million	17,484 Added 25.79%	85,265 $5.09 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $1.21 Million - $1.63 Million	67,781	67,781 $1.63 Million

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $219M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.